Holen Sie sich die Stockscreener-App
43.51
3.10%
1.31
Schlusskurs vom Vortag:
$42.20
Offen:
$42.88
24-Stunden-Volumen:
575.03K
Relative Volume:
0.74
Marktkapitalisierung:
$3.11B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-14.04
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
+5.61%
1M Leistung:
+1.26%
6M Leistung:
+37.26%
1J Leistung:
-6.63%
1-Tages-Spanne:
$42.73
$44.00
1-Wochen-Bereich:
$39.84
$44.00
52-Wochen-Spanne:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
43.51 | 3.02B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Is Kymera Therapeutics Inc. reversing from oversold territoryDay Trade & Safe Capital Preservation Plans - Newser
Will Kymera Therapeutics Inc. outperform tech stocksJuly 2025 Reactions & Community Consensus Trade Signals - 뉴스영
Signal strength of Kymera Therapeutics Inc. stock in tech scannersWeekly Investment Report & Growth Focused Stock Reports - Newser
What is the PEG ratio of Kymera Therapeutics Inc.July 2025 WrapUp & Growth Focused Stock Reports - خودرو بانک
Is Kymera Therapeutics Inc. forming a breakout patternJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - خودرو بانک
Kymera Therapeutics Inc. stock trendline breakdownPortfolio Value Report & Stock Portfolio Risk Control - Newser
Institutional scanner results for Kymera Therapeutics Inc.Earnings Growth Summary & Stock Portfolio Risk Control - Newser
What candlestick patterns are forming on Kymera Therapeutics Inc.July 2025 Reactions & Consistent Income Trade Recommendations - Newser
Is Kymera Therapeutics Inc. stock poised for growth2025 Bull vs Bear & Daily Entry Point Trade Alerts - Newser
Will Kymera Therapeutics Inc. stock recover after recent dropPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about Kymera Therapeutics Inc.2025 Market Outlook & Real-Time Market Trend Scan - Newser
What’s the outlook for Kymera Therapeutics Inc.’s sectorMarket Rally & AI Powered Market Entry Strategies - خودرو بانک
Can technical indicators confirm Kymera Therapeutics Inc.’s reversalQuarterly Profit Summary & Daily Volume Surge Signals - Newser
Should I trade or invest in Kymera Therapeutics Inc.2025 Risk Factors & Stepwise Trade Signal Guides - خودرو بانک
Is Kymera Therapeutics Inc. a play on infrastructure spendingIndex Update & Real-Time Market Sentiment Alerts - خودرو بانک
Sentiment analysis tools applied to Kymera Therapeutics Inc.July 2025 Outlook & High Accuracy Trade Alerts - Newser
What Fibonacci levels say about Kymera Therapeutics Inc. reboundEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Real time social sentiment graph for Kymera Therapeutics Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Will Kymera Therapeutics Inc. stock recover after earnings2025 Support & Resistance & Daily Stock Trend Reports - خودرو بانک
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary - citybiz
Kymera Therapeutics Presents at Citi's 2025 Biopharma Back to School Conference - AInvest
Kymera Names Adams Chief Legal Officer, Corporate Secretary - Bloomberg Law News
Kymera Therapeutics shares rise 2.08% intraday after appointing Brian Adams as Chief Legal Officer. - AInvest
Former Relay Therapeutics CLO Brian Adams Joins Immunology Pioneer Kymera as Legal Chief and Secretary - Stock Titan
Chart overlay techniques for tracking Kymera Therapeutics Inc.Quarterly Trade Review & AI Driven Stock Movement Reports - Newser
Aug Movers: Can Kymera Therapeutics Inc. keep up with sector leaders2025 Market Trends & Short-Term High Return Ideas - خودرو بانک
Kymera Therapeutics Inc. stock outlook for YEAR2025 Retail Activity & Reliable Trade Execution Plans - Newser
How sensitive is Kymera Therapeutics Inc. to inflation2025 Market Trends & Low Risk Growth Stock Ideas - خودرو بانک
Real time breakdown of Kymera Therapeutics Inc. stock performanceTrade Entry Report & Low Drawdown Momentum Trade Ideas - Newser
Visual trend scoring systems applied to Kymera Therapeutics Inc.2025 Momentum Check & Verified High Yield Trade Plans - Newser
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary | KYMR Stock News - GuruFocus
Market Fear: What’s the outlook for Kymera Therapeutics Inc.’s sectorTrade Exit Report & Fast Exit/Entry Strategy Plans - خودرو بانک
Trendlines Suggest Kymera Therapeutics Inc. May Bottom Out SoonVolume Spike & Weekly Breakout Opportunity Watchlist - beatles.ru
How liquid is Kymera Therapeutics Inc. stockJuly 2025 Patterns & AI Powered Trade Plan Recommendations - خودرو بانک
Using data models to predict Kymera Therapeutics Inc. stock movementRecession Risk & Low Risk Entry Point Tips - Newser
How to escape a deep drawdown in Kymera Therapeutics Inc.2025 Volume Leaders & Real-Time Volume Analysis - Newser
Can Kymera Therapeutics Inc. rally from current levels2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Published on: 2025-08-31 12:52:23 - Newser
Kymera Therapeutics Inc. Builds Base for Possible Rebound2025 Trading Volume Trends & Verified Swing Trading Watchlist - beatles.ru
Is Kymera Therapeutics Inc. stock ready for a breakout2025 Momentum Check & Daily Price Action Insights - Newser
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):